<HashMap><database>GEO</database><scores/><additional><omics_type>Genomics</omics_type><species>Homo sapiens</species><gds_type>Genome binding/occupancy profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293855</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Alphavirus M1 disrupts super-enhancer-driven oncogenic transcription in osteosarcoma [ChIP-seq]</name><description>Oncolytic virotherapy has shown promise for various cancers, but its application in osteosarcoma (OS) remains underexplored. This study provides the first evidence of the potent oncolytic activity of M1, a natural Getah-like alphavirus, against OS. We demonstrate that OS cells exhibit heightened sensitivity to M1 infection, with its anti-tumor effects not solely dependent on the canonical ER stress-induced apoptosis. Proteomic and ChIP-seq analyses show the DNA-directed RNA polymerase II subunit RPB1 contributes to oncogenic super-enhancer activity and serves as a direct target of M1-mediated regulation. The oncolytic potency correlated positively with the transcriptional dependency on RPB1 within super-enhancer regions. Mechanistically, the viral non-structural protein NSP2 disrupts super-enhancer activity by recruiting the CUL2-RBX1-ELOC complex, which triggers K63-linked ubiquitination and degradation of RPB1. These findings uncover a previously unrecognized oncolytic mechanism of M1 and its therapeutic potential in OS, with RPB1 as a predictive biomarker for virotherapy response.</description><dates><publication>2026/05/31</publication></dates><accession>GSE293855</accession><cross_references><GSM>GSM8891954</GSM><GSM>GSM8891953</GSM><GSM>GSM8891952</GSM><GSM>GSM8891951</GSM><GSM>GSM8891958</GSM><GSM>GSM8891957</GSM><GSM>GSM8891956</GSM><GSM>GSM8891955</GSM><GPL>24676</GPL><GSE>293855</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>